Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.98 USD
Change Today +0.35 / 1.14%
Volume 57.9K
EBS On Other Exchanges
Symbol
Exchange
New York
As of 12:17 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Fuad El-Hibri

Founder, Executive Chairman, Chairman of Strategic Operations Committee and Member of Pricing Committee, Emergent BioSolutions, Inc.
AgeTotal Calculated CompensationThis person is connected to 115 board members in 3 different organizations across 3 different industries.

See Board Relationships
56$3,591,373
As of Fiscal Year 2014

Background*

Mr. Fuad El-Hibri has been Chairman of the Board and Chief Executive Officer of Emergent Biodefense Operations Lansing Inc., a subsidiary of Emergent Biosolutions Inc. since June 2004. Mr. El-Hibri founded Emergent Biosolutions Inc. in 2004 and has been its Executive Chairman since June 2004. He served as Chief Executive Officer of Emergent Biosolutions Inc from June 2004 to April 01, 2012. He served as the President of Emergent BioSolutions, Inc. from March 2006 to ...

Read Full Background

Corporate Headquarters*

400 Professional Drive
Gaithersburg, Maryland 20879

United States

Phone: 240-631-3200
Fax: --

Board Members Memberships*

Former Chairman
Director
Chairman and Chief Executive Officer
2004-Present
Founder, Executive Chairman, Chairman of Strategic Operations Committee and Member of Pricing Committee

Education*

BA
Stanford University
Master's Degree
Yale University

Other Affiliations*

Annual Compensation*

Salary$881,493
Total Annual Compensation$881,493

Stock Options*

Restricted Stock Awards$1,579,782
All Other Compensation$7,800
Exercisable Options341,400
Exercisable Options Value$3,196,754
Unexercisable Options151,042
Unexercisable Options Value$471,946
Total Value of Options$3,668,700
Total Number of Options492,442

Total Compensation*

Total Annual Cash Compensation$889,293
Total Short Term Compensation$881,493
Other Long Term Compensation$1,587,582
Total Calculated Compensation$3,591,373
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBS:US $30.98 USD +0.35

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$860.0K
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
$620.1K
William S. Marth Chief Executive Officer, President and Director
Albany Molecular Research Inc.
$982.5K
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
567.0K GBP
M. Michelle Berrey M.D., MPH.Chief Executive Officer, President, Chief Medical Officer and Director
Chimerix, Inc.
$419.3K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.